<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The prognostic significance of microsatellite instability (MSI) in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) has been addressed in many studies since the initial description of better survival rates in MSI-positive (MSI+) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> than in MSI-negative (MSI-) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have demonstrated that a higher degree of hypomethylation of long interspersed nuclear element-1 (L1) is related to poor prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and that a wide variation of L1 methylation levels exist within MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to identify whether L1 and Alu methylation status could predict clinical outcomes within MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed 207 MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> for their methylation levels in L1 and Alu repetitive DNA elements using pyrosequencing and correlated them with clinicopathological information including survival data </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Univariate survival analysis showed that low Alu methylation status (&lt;18.60%) and low L1 methylation status (&lt;53.00%) were significantly associated with shorter overall survival time (log-rank test, P = 0.009 and P &lt; 0.001, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis using nine parameters (Alu methylation status, L1 methylation status, patient's age, disease stage [<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, node, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> staging system], differentiation, Crohn-like lymphoid reaction, KRAS/BRAF mutation status, CpG island methylator phenotype [CIMP] status, and peritumoral <z:e sem="disease" ids="C1262091" disease_type="Disease or Syndrome" abbrv="">lymphocytic infiltration</z:e>), which were significantly prognostic in MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, revealed that low L1 methylation status was an independent prognostic factor of MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> (P = 0.009), whereas low Alu methylation status was not </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Clinical outcomes of MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> depend on L1 methylation status, suggesting that lower L1 methylation status serves as a significant prognostic parameter of adverse prognosis in MSI+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
</text></document>